Search
Flavin-containing monooxygenase 3
go.drugbank.com/bio_entities/BE0003606EnzymeHumansEssential hepatic enzyme that catalyzes the oxygenation of a wide variety of nitrogen- and sulfur-containing compounds including drugs as well as dietary compounds (PubMed:10759686, PubMed:30381441, PubMed:32156684). Plays an important r...
Synonyms: FMO form 2Teprasiran
go.drugbank.com/drugs/DB15064InvestigationalTeprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery).
Parsatuzumab
go.drugbank.com/drugs/DB14897InvestigationalRecurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)). … Parsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or
Clopamide
go.drugbank.com/drugs/DB13792InvestigationalLike thiazide diuretics, it has an aromatic sulfonamide base but with no double-ring structure.
LI-301
go.drugbank.com/drugs/DB05509ExperimentalThis results in a slight dulling of sensation that can be used to treat premature ejaculation without interfering with normal sexual pleasure or orgasm. … LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water.
Vapitadine
go.drugbank.com/drugs/DB05738ExperimentalVapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis
Brasofensine
go.drugbank.com/drugs/DB04857ExperimentalBrasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.
Omiganan
go.drugbank.com/drugs/DB06610InvestigationalOmiganan has been investigated for the treatment of Mupirocin-resistant MRSA skin infections.
SIG-001
go.drugbank.com/drugs/DB17826InvestigationalSIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer
Colestilan chloride
go.drugbank.com/drugs/DB11634ApprovedWithdrawnColestilan is an ingredient in the EMA-withdrawn product BindRen.
Categories: Drugs for Treatment of Hyperkalemia and Hyperphosphatemia